FeesSafety
Pluang+

Evaxion's personalized cancer vaccine EVX-01 shows sustained responses in advanced melanoma after 3 years.

Company Fundamentals
19 Oct 2026, 10:00 WIB
GlobeNewsWire
View Source
Bullish
Evaxion's personalized cancer vaccine EVX-01 shows sustained responses in advanced melanoma after 3 years.

Evaxion announced that their personalized cancer vaccine EVX-01 maintained clinical responses in all advanced melanoma patients at a three-year follow-up in a phase 2 trial, with no tumor progression observed. Initially combined with Merck's KEYTRUDA, EVX-01 was given as stand-alone therapy in the third year, showing durable benefits including a 75% objective response rate and 25% complete response rate at two years. These results highlight the vaccine's potential as a novel immunotherapy and will be presented at the ESMO 2026 Congress, supporting further development and partnership opportunities.

Evaxion's personalized cancer vaccine EVX-01 clinical results provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 79 rose and 65 fell. Notable movers include IDXX at USD 560.36 with a 1-day change of +5.93%, COO at USD 57.94 with +5.58%, and ACHC at USD 29.98 with -5.34%.

More News

NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA's Board of Directors has established the National Security and Export Control Oversight Committee to manage the company's national security policies and export control compliance. Chaired by Suzanne Nora Johnson, the committee will oversee NVI...

Market News
Neutral
1 hour ago
Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market is projected to grow from $13.85 billion in 2027 to $25.65 billion by 2032, with a CAGR of 13.12%. Growth is fueled by increased smartphone use, digital wallet adoption, expanding logistics, and social commerce. B2C remai...

Market News
Bullish
1 hour ago
Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock Biotech Limited announced its 2026 Annual General Meeting will be held on December 22, 2026, at its Shanghai office. The meeting will cover ratifying Ernst & Young Hua Ming LLP as auditor for 2026, re-electing directors Zhihong Zhang and...

Company Fundamentals
Neutral
1 hour ago
Bernstein SocGen downgrades PepsiCo to Underperform amid weak demand and rising costs

Bernstein SocGen downgrades PepsiCo to Underperform amid weak demand and rising costs

Bernstein SocGen Group downgraded PepsiCo's stock rating from Market Perform to Underperform due to weak North American demand, rising input costs, and margin pressures. PepsiCo's shares have fallen 2.4% over the past six months, underperforming its ...

Analyst Insights
Bearish
2 hours ago
Atos secures contract to manage and unify France's shared medical records platform with Mon Espace Santé.

Atos secures contract to manage and unify France's shared medical records platform with Mon Espace Santé.

Atos has been selected by France's Caisse nationale de l’Assurance Maladie (Cnam) to manage and secure the Dossier Médical Partagé (DMP) and integrate it with Mon Espace Santé (MES) into a unified digital health platform. This platform, serving over ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App